Punnee Pitisuttithum

List of Publications by Year
in descending order

114 papers	13,431 citations	76326 40 h-index	25787 108 g-index
116 all docs	116 docs citations	116 times ranked	10123 citing authors

#	Article	IF	Citations
1	Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. New England Journal of Medicine, 2009, 361, 2209-2220.	27.0	2,748
2	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. New England Journal of Medicine, 2012, 366, 1275-1286.	27.0	1,699
3	A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. New England Journal of Medicine, 2015, 372, 711-723.	27.0	1,090
4	Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet, The, 2014, 384, 1358-1365.	13.7	829
5	Randomized, Doubleâ€Blind, Placeboâ€Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIVâ€1 Vaccine among Injection Drug Users in Bangkok, Thailand. Journal of Infectious Diseases, 2006, 194, 1661-1671.	4.0	755
6	Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. Science Translational Medicine, 2014, 6, 228ra39.	12.4	412
7	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. Immunity, 2013, 38, 176-186.	14.3	374
8	Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9019-9024.	7.1	371
9	Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines. Science Translational Medicine, 2014, 6, 228ra38.	12.4	367
10	Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family. Journal of Virology, 2012, 86, 11521-11532.	3.4	357
11	Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. Journal of Infectious Diseases, 2012, 206, 431-441.	4.0	273
12	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet, The, 2018, 392, 232-243.	13.7	269
13	Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection. PLoS ONE, 2014, 9, e87572.	2.5	248
14	COMPASS identifies T-cell subsets correlated with clinical outcomes. Nature Biotechnology, 2015, 33, 610-616.	17.5	232
15	Activity of posaconazole in the treatment of central nervous system fungal infections. Journal of Antimicrobial Chemotherapy, 2005, 56, 745-755.	3.0	225
16	Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial. PLoS ONE, 2013, 8, e75665.	2.5	214
17	The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. AIDS Research and Human Retroviruses, 2012, 28, 1444-1457.	1.1	191
18	HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. Journal of Virology, 2014, 88, 7715-7726.	3.4	169

#	Article	IF	Citations
19	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathogens, 2015, 11, e1005042.	4.7	145
20	Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1997-2008.	2.5	137
21	Immunogenicity and Safety of a 9-Valent HPV Vaccine. Pediatrics, 2015, 136, e28-e39.	2.1	105
22	Dengue and Other Common Causes of Acute Febrile Illness in Asia: An Active Surveillance Study in Children. PLoS Neglected Tropical Diseases, 2013, 7, e2331.	3.0	99
23	FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. Journal of Clinical Investigation, 2014, 124, 3879-3890.	8.2	99
24	Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion. Journal of Virology, 2013, 87, 1554-1568.	3.4	97
25	Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. Vaccines, 2021, 9, 1413.	4.4	77
26	Safety and Immunogenicity of Combinations of Recombinant Subtype E and B Human Immunodeficiency Virus Type 1 Envelope Glycoprotein 120 Vaccines in Healthy Thai Adults. Journal of Infectious Diseases, 2003, 188, 219-227.	4.0	65
27	Phase I/II Study of a Candidate Vaccine Designed Against the B and E Subtypes of HIV-1. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1160-1165.	2.1	65
28	Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved. Immunity, 2014, 41, 909-918.	14.3	65
29	Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees. Journal of Virology, 2013, 87, 7828-7836.	3.4	59
30	Infant HIV Type 1 gp120 Vaccination Elicits Robust and Durable Anti-V1V2 Immunoglobulin G Responses and Only Rare Envelope-Specific Immunoglobulin A Responses. Journal of Infectious Diseases, 2015, 211, 508-517.	4.0	57
31	Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. Journal of Infectious Diseases, 2017, 215, 1255-1263.	4.0	57
32	V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. PLoS ONE, 2017, 12, e0180720.	2.5	55
33	COVID-19 vaccine strategies must focus on severe disease and global equity. Lancet, The, 2022, 399, 406-410.	13.7	55
34	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. PLoS Computational Biology, 2015, 11, e1003973.	3.2	51
35	Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccinees. PLoS Computational Biology, 2015, 11, e1004185.	3.2	50
36	Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand. PLoS ONE, 2011, 6, e27837.	2.5	48

#	Article	IF	Citations
37	HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. Science Translational Medicine, 2015, 7, 296ra112.	12.4	47
38	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine, 2016, 14, 97-111.	6.1	47
39	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. Journal of Virology, 2018, 92, .	3.4	46
40	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. Journal of Virology, 2018, 92, .	3.4	45
41	Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to Î±4Î²7 Integrin Receptor. PLoS ONE, 2015, 10, e0143895.	2.5	41
42	9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV. Expert Review of Vaccines, 2015, 14, 1405-1419.	4.4	38
43	Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens. AIDS Research and Human Retroviruses, 2017, 33, 410-423.	1.1	38
44	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathogens, 2017, 13, e1006182.	4.7	38
45	Health education and factors influencing acceptance of and willingness to pay for influenza vaccination among older adults. BMC Geriatrics, 2015, 15, 136.	2.7	36
46	Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Papillomavirus Research (Amsterdam, Netherlands), 2020, 10, 100203.	4.5	34
47	Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. Lancet HIV,the, 2020, 7, e238-e248.	4.7	33
48	A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future. Vaccine, 2021, 39, 6573-6584.	3.8	32
49	The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection. Expert Review of Vaccines, 2016, 15, 795-798.	4.4	30
50	HIVâ€specific antibodyâ€dependent phagocytosis matures during HIV infection. Immunology and Cell Biology, 2014, 92, 679-687.	2.3	29
51	Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial. Lancet Infectious Diseases, The, 2018, 18, 1260-1268.	9.1	28
52	Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2017, 17, 833-842.	9.1	27
53	Aggregate complexes of HIV-1 induced by multimeric antibodies. Retrovirology, 2014, 11, 78.	2.0	26
54	Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. EClinicalMedicine, 2022, 45, 101323.	7.1	26

#	Article	IF	Citations
55	Establishment of a Shigella sonnei human challenge model in Thailand. Vaccine, 2012, 30, 7040-7045.	3.8	25
56	Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults. Vaccine Journal, 2016, 23, 564-575.	3.1	25
57	HIV-1 Prophylactic Vaccine Trials in Thailand. Current HIV Research, 2005, 3, 17-30.	0.5	22
58	Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine â€“ A combined analysis of five phase III clinical trials. Papillomavirus Research (Amsterdam, Netherlands), 2017, 3, 105-115.	4.5	22
59	A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial. Lancet Infectious Diseases, The, 2018, 18, 58-67.	9.1	22
60	Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group. Vaccine, 2017, 35, 7339-7346.	3.8	21
61	Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. Journal of Virology, 2017, 91, .	3.4	19
62	Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges. Expert Review of Vaccines, 2020, 19, 133-142.	4.4	19
63	Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. Journal of Virology, 2020, 94, .	3.4	19
64	HIV vaccine delayed boosting increases Env variable region 2â€“specific antibody effector functions. JCI Insight, 2020, 5, .	5.0	18
65	HIV vaccine research in Thailand: lessons learned. Expert Review of Vaccines, 2008, 7, 311-317.	4.4	17
66	Etiology, Clinical Course, and Outcomes of Pneumonia in the Elderly: A Retrospective and Prospective Cohort Study in Thailand. American Journal of Tropical Medicine and Hygiene, 2021, 104, 2009-2016.	1.4	17
67	Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. Journal of Virology, 2014, 88, 9406-9417.	3.4	16
68	Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials. Clinical Infectious Diseases, 2018, 66, 1164-1172.	5.8	16
69	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. PLoS ONE, 2020, 15, e0226803.	2.5	16
70	Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers. Clinical Infectious Diseases, 2021, 72, 2035-2041.	5.8	15
71	Clinical Factors for Severity of Plasmodium falciparum Malaria in Hospitalized Adults in Thailand. PLoS ONE, 2013, 8, e71503.	2.5	15
72	HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial. Immunogenetics, 2014, 66, 299-310.	2.4	14

#	Article	IF	Citations
73	IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens. AIDS Research and Human Retroviruses, 2015, 31, 1178-1186.	1.1	14
74	Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. PLoS ONE, 2018, 13, e0196397.	2.5	14
75	Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. EBioMedicine, 2015, 2, 713-722.	6.1	13
76	HIV Incidence and Risk Behaviours of People Who Inject Drugs in Bangkok, 1995â€“2012. EClinicalMedicine, 2019, 9, 44-51.	7.1	13
77	Safety and immune responses following administration of H1N1 live attenuated influenza vaccine in Thais. Vaccine, 2013, 31, 1503-1509.	3.8	12
78	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. PLoS ONE, 2017, 12, e0176428.	2.5	12
79	Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1. ELife, 2021, 10, .	6.0	12
80	Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response. JCI Insight, 2020, 5, .	5.0	12
81	Three-Year Follow-up of 2-Dose Versus 3-Dose HPV Vaccine. Pediatrics, 2021, 147, .	2.1	11
82	A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection. Scientific Reports, 2017, 7, 1057.	3.3	10
83	Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. JCI Insight, 2016, 1, e88522.	5.0	10
84	Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines. EClinicalMedicine, 2021, 37, 100976.	7.1	9
85	Beyond RV144 Efficacy Results: An Update. Procedia in Vaccinology, 2013, 7, 49-56.	0.4	8
86	A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination. Cell Reports Medicine, 2021, 2, 100386.	6.5	8
87	Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans. Journal of Virology, 2018, 92, .	3.4	7
88	Vaccine Update: Recent Progress With Novel Vaccines, and New Approaches to Safety Monitoring and Vaccine Shortage. Journal of Clinical Pharmacology, 2018, 58, S123-S139.	2.0	6
89	Social harms in injecting drug users participating in the first phase III HIV vaccine trial in Thailand. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2007, 90, 2442-8.	0.1	6
90	Issues in Women's Participation in a Phase III Community HIV Vaccine Trial in Thailand. AIDS Research and Human Retroviruses, 2013, 29, 1524-1534.	1.1	5

#	Article	IF	Citations
91	An HIV Vaccine for South-East Asiaâ€"Opportunities and Challenges. Vaccines, 2013, 1, 348-366.	4.4	5
92	Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease. PLoS ONE, 2018, 13, e0207878.	2.5	5
93	Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1898-1903.	1.4	5
94	RV306, an Evaluation of a 48 Week ALVAC-HIV AIDSVAX B/E Vaccination Regimen in Thailand: Participation Rates for Optional Specimen Collections. AIDS Research and Human Retroviruses, 2014, 30, A264-A264.	1.1	4
95	A 9-Valent HPV Vaccine Against Infection and Intraepithelial Neoplasia in Women. Obstetrical and Gynecological Survey, 2015, 70, 446-448.	0.4	4
96	Risk Factors for HIV sero-conversion in a high incidence cohort of men who have sex with men and transgender women in Bangkok, Thailand. EClinicalMedicine, 2021, 38, 101033.	7.1	4
97	Social restriction versus herd immunity policies in the early phase of the SARS-CoV-2 pandemic: A mathematical modelling study. Asian Pacific Journal of Allergy and Immunology, 2022, , .	0.4	4
98	Knowledge, attitude, and practices toward COVID-19 among the international travelers in Thailand. Tropical Diseases, Travel Medicine and Vaccines, 2021, 7, 29.	2.2	4
99	Accelerating the development of an AIDS vaccine: the AIDS vaccine for Asia Network (Avan). Southeast Asian Journal of Tropical Medicine and Public Health, 2011, 42, 1130-46.	1.0	4
100	Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario. Vaccine, 2022, 40, 1968-1976.	3.8	4
101	Expectation of Volunteers Towards the Vaccine Efficacy of the Prime-Boost HIV Vaccine Phase III Trial During Unblinding. AIDS Research and Human Retroviruses, 2014, 30, 1041-1045.	1.1	3
102	Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying env from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism. Journal of Virology, 2018, 92, .	3.4	3
103	Vaccine development lessons between HIV and COVID-19. Lancet Infectious Diseases, The, 2021, 21, 759-761.	9.1	3
104	Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand. PLoS ONE, 2015, 10, e0127998.	2.5	2
105	Integrated Systems Biology Analysis Reveals Contrasting Role for Innate Immune Response Genes in Conferring Risk of Infection in RV144 Trial. AIDS Research and Human Retroviruses, 2014, 30, A15-A16.	1.1	1
106	A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand. Human Vaccines and Immunotherapeutics, 2019, 15, 2440-2445.	3.3	1
107	A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses. Vaccine, 2020, 38, 852-858.	3.8	1
108	Selecting participants fairly for controlled human infection studies. Bioethics, 2020, 34, 771-784.	1.4	1

#	Article	IF	Citations
109	A Quantitative Approach to Unravel the Role of Host Genetics in IgG-FcÎ³R Complex Formation After Vaccination. Frontiers in Immunology, 2022, 13, 820148.	4.8	1
110	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. AIDS Research and Human Retroviruses, 2014, 30, A25-A26.	1.1	0
111	F-108â€ƒThe role of a dual pre- and post- entry innate and adaptive immune mechanism in protection against HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 63.	2.1	0
112	Family Based Directly Observed Therapy on Culture Conversion in Newly Diagnosed Pulmonary Tuberculosis Patients. American Journal of Public Health Research, 2014, 2, 147-152.	0.3	0
113	Costs of Chronic Hepatitis B patients in a developing country. Journal of Nursing Education and Practice, 2014, 4, .	0.2	0
114	Adherence and Health Problems in Thai Travellers Living with HIV. Tropical Medicine and Infectious Disease, 2022, 7, 128.	2.3	0